The 2025 IASLC World Conference on Lung Cancer is underway in Barcelona, Spain, bringing together the world’s leading experts in lung cancer and thoracic oncology. This annual conference serves as a critical forum for clinicians, researchers, and industry leaders to explore the latest scientific discoveries, innovative treatments, and emerging trends in lung cancer care.
Attendees are engaging in high-level discussions, interactive workshops, and cutting-edge presentations, fostering collaboration and driving forward global efforts to improve outcomes for patients affected by lung cancer.
Our team at OncoDaily has selected a few posts from WCLC 2025 that you should not miss!
“Dr. Paul Van Schil delivers his IASLC Presidential Address at WCLC25, reflecting on the advances and accomplishments, growth, collaboration, and progress. He now passes the IASLC Presidency to Professor Caicun Zhou as we move into the new year.”
“Today at WCLC25 it was all about flaura2 vs mariposa. Two good first line options for patients with nsclc and egfr mutation.
However let’s think about the following when considering what to give:
– both regimens have more toxicity than single agent osi
– both expensive one more so than the other
– if you start with flaura2 regimen you can’t give amivantamab in the second line for now since no data
– mariposa showed an early os advantage. Flaura2 took some time to do so! Why is this?
– patients who eventually progress on flaura2 can be rechallenged with platinum but can you continue osi with it?
– translational component of mariposa shows higher suppression of emergence of complex resistant mechanism. Is this important in clinical practice ?
– there appears to be a higher reponse rate with maripossa. This would be important in symptomatic patients with high disease burden.”
“WCLC25 Lung IO orals
Do ICIs work as well in pts>80y (IFCT-1805: Atezo+chemo) or those with brain mets (NivIpi-Brain)?
– not as well
– IFCT: no OS benefit
Celine Mascaux
– NivIpi: mPFS 4.9m, mOS 10.5m
Nadal Ernest
Expertly discussed by Hendriks Lizza.”
“Thank you so much Stephen V Liu for your leadership in scientific communication, and for being the glue that brings together the IASLC family.”
“Surgical outcomes correlation with 5 year survival with neoadjuvant chemo IO for lung cancer in CheckMate 816 presented by the legendary Prof. Tetsuya Mitsudomi WCLC25 overall v good outcomes, remarkably so for patients with pneumonectomy.”
“Very old patients (>80 y) are a neglected population unrepresented and unreported in trials with ICI. Immunesenescence and chronic state of low grade inflammation know as INFLAMAGING expose old pts to higher risk of irAEs as reported in ELDERLY study (1.5% toxic deaths).”
“It’s official: LungCancerRx has gone global! Excited to record 2 live episodes straight from WCLC25 in Barcelona. Featuring my colleagues Bruna Pellini, Stephen V Liu and Antonio Calles. Missing Aakash Desai, Fawzi Abu Rous!”
“ROS1+ lung cancer is rare, but patients are not invisible. At WCLC25 Dr Alex Drilon ARROS1 shows science is working for them too in a pivotal trial for ALL ROS1 patients, with activity in brain mets and TRK-sparing – can mean fewer burdens & longer time on treatment.”
“WCLC 2025: $SMMT While investigators of HARMONi still maintained in a presentation that the PFS benefit was consistent across all predefined subgroups, a longer-term follow-up showed that, in European and North American patients, ivonescimab’s PFS improvement was 33% (hazard ratio 95% CI: 0.45-1.00), which is notably lower than the 45% recorded by Chinese patients. The risk reduction for the overall trial was 43% at the longer follow-up.
While PFS met its overall mark in HARMONi, ivonescimab has disappointed when it comes to overall survival (OS), missing the trial’s other dual primary endpoint.
The presentation at WCLC confirms that HARMONi missed OS at its final analysis. Confirming what Summit had previously disclosed, the death risk was 21% (HR 95% CI: 0.62-1.01) in favor of ivonescimab and chemo, with a p value of 0.057, while the statistical significance bar was set at a p value of 0.0448.”
“We must pass the fascination phase and study young lung cancer
Today we present the results of the largest study evaluating the psychosocial needs of young patients with lung cancer.
Join us today at our poster presentation Poster station 2 2:23 PM at WCLC25.”
“Our TRANSiTION project coordinator is at WCLC25 , Barcelona where final results are presented! Excited that the impact of our work gains even more momentum around the world.”
“With such exciting OS data- (HR=O.77, median OS improved by just about 1 year) osi said to chemo: “i do” and i am just Flaura’d!
The wedding here will actually be quite cheap for chemo- Flaural arrangements by AZ…
How does this compare to MARIPOSA? I say isn’t nice to have both Sinner AND Alcaraz available to play for better outcomes for our patients?”
“Dr. John Varlotto presents EA5181: phase II study of cuncurrent and consolidation durvalumab vs consolidation alone after CRT in unresectable stage III NSCLC at WCLC25. Superimposable curves: no improvement at all in OS (HR 1.03) or PFS (1.05) and similar toxicity.”
“Stephen V Liu and the IASLC communication staff in action at WCLC25! On bhealf of all the co – chairs: Thank you!”
“Grateful to reconnect with my mentor, Prof. David Planchard, at WCLC 2025.
The time at Gustave Roussy shaped my path in thoracic oncology and continues to inspire my work today.”
“Honored to receive the Early Career Education Award at WCLC25
Grateful to my mentors, colleagues, and collaborators for their constant support.
Excited to keep contributing to lung cancer research and education worldwide.”
“Environmental exposure does matter for NSCLC.
Provocative data on air pollution and radon effects on NSCLC screening and tumour microenvironment.
Pollution associated with higher adenok risk and radon correlated with more inflammed (TILs PDL1+) TME.”
“Brain mets in NSCLC
-Asymptomatic → upfront targeted therapy (TT, even w/ low iORR)
-Symptomatic → local ± TT
Decisions still specialty-driven
Next step: reshape practice with clinical trial.”
“Key phase 3 ongoing trials in limited stage sclc. The field is def expanding!”
“The big question: Should osimertinib monotherapy still be considered the default frontline strategy?
With these OS data presented by Dr. David Planchard at the plenary session at the hashtag#WCLC, FLAURA2 doesn’t just add months – it rewrites how we think about sequencing and treatment intensity in EGFR-mutant NSCLC.
The field now faces a critical decision: stick with the simplicity of monotherapy, or embrace the survival edge of combination treatmentss
Is it time to move beyond osi monotherapy as the standard of care?”
“It’s not even light yet in Barcelona and Team LuCE is starting the day with our 1st meeting. Hard to believe WCLC2025 is already halfway through – so many big conversations on lung cancer and great to get to spend time with others who are passionate about improving outcomes. Thanks to IASLC for making it all possible! ”
“EDU session at WCLC25
Advancing EGFR mutant NSCLC opportunities, sequencing approaches, LMD and SNC disease by Jessica Menis, Aaron Tan, Rossana Ruiz, Helena Yu, EGFR Resisters.”
“Science is about data but also friends and community we belong!
This is WCLC2025 for me. Great science and big friends!”
“Dr. Paul Van Schil says the second WCLC25 Presidential Symposium will include groundbreaking abstracts and key developments in lung cancer treatment.
Read a preview in ILCN.”
“Dr. John Varlotto presents EA5181: phase II study of cuncurrent and consolidation durvalumab vs consolidation alone after CRT in unresectable stage III NSCLC at WCLC25. Superimposable curves: no improvement at all in OS (HR 1.03) or PFS (1.05) and similar toxicity.”
“Exciting new data in the era of ADCs for tx SCLC. Great news for patients to have early access to these novel therapies. We need more translational studies for predictive biomarkers to inform treatment selection, sequencing and combinatorial studies.”
“Question
The FLAURA2 trial showed an OS benefit with osimertinib + ct vs osimertinib alone in 1L EGFR+ NSCLC.
Here’s the rw dilemma: For a pt with disease control or ongoing response on osimertinib monotherapy, should we proactiv add ct?”
“It’s hard to miss the passion from Erin Gillaspie when she discusses lung cancer patients and how to improve outcomes with early and locally advanced disease. She reviewed the rates of resection following neoadj IO and the thoughts of procedures.”
“NeoADAURA MRD analysis
ctDNA-based, tumour-informed MRD assay showed higher sensitivity than single EGFR testing
Baseline MRD was prognostic for EFS Osimertinib (± CTx) improved MRD clearance vs placebo + CTx
Pre-surgical MRD clearance / MRD-negative status linked with higher MPR
MRD may complement MPR as a key endpoint, supporting neoadjuvant osimertinib in resectable EGFRm stage II–III NSCLC.”
“Congratulations Joyce Chen on this beautiful poster examining real-world NSCLC biomarker testing practices and barriers/facilitators through interviews + the IASLC Global Survey. Check out the eposter and video too!”
“Team Ireland WCLC25 Ireland’s lung cancer team at WCLC25 — nurses, surgeons, oncologists, scientists & advocates, working for patients.”
“Happy to take part in IASLC podcast during WCLC2025 highlighting the important involvement of thoracic surgeons in the current era of thoracic oncology.”
“What an achievement for ROS1 patients.
Alex Drilon reported the updated result of the ARROS1 trial. Impressive RR (89#) and duration of response with favorable safety profile in naive pts treated with Zidesamtinib.”
“Amazing to meet medical students from around the world who are ALREADY passionate about improving outcomes for patients with lung cancer!! Especially ones mentored by my brother Fawzi Abu Rous who bring treats!!”
“Teamwork in action at WCLC25! Our RAs Angela Morabito and Lauren Kiel joined Dr. Florez at the poster stand – sharing our research, answering questions, and connecting with colleagues worldwide. Proud of our lab team!”
